Glycopyrrolate - Sunovion Respiratory Development/PARI Pharma

Drug Profile

Glycopyrrolate - Sunovion Respiratory Development/PARI Pharma

Alternative Names: EP-101; Glycopyrrolate bromide; Lonhala Magnair; SUN-101; SUN-101/eFlow®

Latest Information Update: 05 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Elevation Pharmaceuticals
  • Developer PARI Pharma GmbH; Sunovion Respiratory Development
  • Class Antiasthmatics; Antispasmodics; Antiulcers; Pyrrolidines; Quaternary ammonium compounds; Skin disorder therapies; Small molecules
  • Mechanism of Action Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic obstructive pulmonary disease
  • Phase II Asthma

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 04 Apr 2018 Launched for Chronic obstructive pulmonary disease in USA (Inhalation)
  • 05 Dec 2017 Sunovion Pharmaceuticals announces intention to launch glycopyrrolate in the US in early 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top